title: Treatment and developmental therapeutics in aspergillosis. 1. Amphotericin B and its derivatives.
abstract: In recent years, the frequency of infections caused by Aspergillus sp. has been on the rise. Immunocompromised patients are especially vulnerable to such infections. The polyene antibiotic amphotericin B is currently considered to be therapeutically the most effective drug against Aspergillus-induced infections. In the present review, the clinical efficacy of amphotericin B, its toxicities and various routes of applications, are discussed. Different combinations of amphotericin B with other drugs have also been reviewed, along with the anti-Aspergillus activity of various other antibiotics and some ester derivatives of amphotericin B.
authors: National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892.
authors: V S
authors: VS
authors: Georgiev
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000276:immunology; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D008172:Lung Diseases, Fungal / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D000666:Amphotericin B